language:english – DEARGEN UPDATES

2020년 9월 22일2020년 9월 23일

Notice (English Version)

this is notice post excerpt

2020년 8월 25일2020년 9월 22일

[Press Release] Optipharm and Deargen start developing vaccine for liver cancer treatment using AI

Optipharm and Deargen, Introduced AI to find antigens (epitopes) that cause immune responses to liver cancer cells.

2020년 8월 13일2020년 9월 22일

[Event] DEARGEN, in ‘KOREA Pharm and Bio 2020’ Fair

DEARGEN participated in KOREA PHARM & BIO 2020 fair in KOREA and received a lot of interest. Especially for the case of COVID-19 treatment prediction using AI.

2020년 3월 23일2020년 9월 24일

Five Companies Using AI to Fight Coronavirus

Deep learning models predict old and new drugs that might successfully treat COVID-19.

2020년 2월 7일2020년 9월 22일

Deargen Predicted Potential Antivirals for The Novel Coronavirus Infection using AI

Deargen, predicted a drug with high potential for treatment of a new coronavirus (2019-nCoV) using the deep-learning technology based AI model MT-DTI. The work is published on the BioRxiv.

2020년 2월 5일2020년 9월 22일

MolEQ, an artificial intelligence model that adjusts multiple property at the same time and optimizes small-molecule lead compounds

Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at the Advancing Precision Medicine Drug Development : Incorporation of Real-World Data and Other Novel Strategies Special Conference which was held from AACR on January 9 – 12.

2019년 9월 3일2020년 9월 22일

First-in Class Drug Targeting DDT2 (Code Name) Transcription Factor for Primary Cancers

We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS.

2019년 8월 14일2020년 9월 22일

A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.

Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR).

2019년 8월 12일2020년 9월 22일

[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.

Deargen Inc. Presented at MLHC 2019, “All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”.

2019년 8월 5일2020년 9월 22일

Treatment of Sarcopenia using Small Molecules

Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules.